"So it's another piece of the pie, another proof of evidence that the semaglutide is working on those systems in the brain that we know are important for addiction." Leggio is now working on a protocol for a randomized controlled trial that will look at semaglutide and alcohol use in humans and collaborating with Oklahoma State University on a similar study
This triple-receptor activity distinguishes retatrutide from earlier incretin mimetics such as semaglutide (a pure GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist)
Upon initiating therapy, the endocrinologist ensures appropriate dose titration to minimise GI side effects, provides education on injection technique and timing, and establishes therapeutic goals, such as glycaemic control, weight reduction, and improvement in cardiometabolic risk
It has also been referenced in studies probing neuronal signalling cascades and receptor activation kinetics in controlled laboratory settings
So it doesn't sit there forever because the glutathione is a very short life also
Retatrutide produces substantially greater A1C reductions than metformin monotherapy